Related Experiment Video
Updated: Mar 11, 2026
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease:
Robert A Hauser1, Ruosha Li2, Adriana Pérez2
1Departments of Neurology, Molecular Pharmacology and Physiology, University of South Florida, Parkinson's Disease and Movement Disorders Center, National Parkinson Foundation Center of Excellence, Tampa FL, USA.
Background:
Monoamine oxidase type B (MAO-B) inhibitors exhibit neuroprotective effects in preclinical models of PD but clinical trials have failed to convincingly demonstrate disease modifying benefits in PD patients.
Objective:
To perform a secondary analysis of NET-PD LS1 to determine if longer duration of MAO-B inhibitor exposure was associated with less clinical decline.
Methods:
The primary outcome measure was the Global Outcome (GO), comprised of 5 measures: change from baseline in the Schwab and England (ADL) scale, the 39-item Parkinson's Disease Questionnaire (PDQ-39), the UPDRS Ambulatory Capacity Scale, the Symbol Digit Modalities Test, and the most recent Modified Rankin Scale. A linear mixed model was used to explore the association between the cumulative duration of MAO-B inhibitor exposure and the GO, adjusting for necessary factors and confounders. Associations between MAO-B inhibitor exposure and each of the five GO components were then studied individually.
Results:
1616 participants comprised the analytic sample. Mean observation was 4.1 (SD = 1.4) years, and 784 (48.5%) participants received an MAO-B inhibitor. The regression coefficient of cumulative duration of MAO-B inhibitor exposure (in years) on the GO was - 0.0064 (SE = 0.002, p = 0.001). Significant associations between duration of MAO-B inhibitor exposure and less progression were observed for ADL (p < 0.001), Ambulatory Capacity (p < 0.001), and the Rankin (p = 0.002).
Conclusions:
Our analysis identified a significant association between longer duration of MAO-B inhibitor exposure and less clinical decline. These findings support the possibility that MAO-B inhibitors slow clinical disease progression and suggest that a definitive prospective trial should be considered.
Insights
Longer use of MAO-B inhibitors in Parkinson's disease (PD) patients was linked to slower clinical decline. This suggests MAO-B inhibitors may modify PD progression, warranting further investigation in prospective trials.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Neurology
Background:
- Monoamine oxidase type B (MAO-B) inhibitors show neuroprotection in preclinical Parkinson's disease (PD) models.
- Clinical trials have not conclusively demonstrated disease-modifying benefits in PD patients.
Purpose of the Study:
- To conduct a secondary analysis of the NET-PD LS1 dataset.
- To investigate if extended exposure to MAO-B inhibitors correlates with reduced clinical decline in PD patients.
Main Methods:
- Utilized a linear mixed model to analyze the association between cumulative MAO-B inhibitor exposure duration and the Global Outcome (GO).
- The GO comprised five measures: ADL scale, PDQ-39, UPDRS Ambulatory Capacity, Symbol Digit Modalities Test, and Modified Rankin Scale.
- Adjusted for relevant factors and confounders, and examined individual GO components.
Main Results:
- Analyzed data from 1616 participants with a mean observation of 4.1 years; 784 (48.5%) received MAO-B inhibitors.
- Found a significant association between longer MAO-B inhibitor exposure duration and less clinical decline (regression coefficient = -0.0064, p=0.001).
- Significant associations were observed for ADL (p<0.001), Ambulatory Capacity (p<0.001), and Rankin scale (p=0.002).
Conclusions:
- Longer duration of MAO-B inhibitor exposure is associated with slower clinical progression in Parkinson's disease.
- These findings suggest MAO-B inhibitors may slow disease progression.
- A definitive prospective trial to confirm these effects is recommended.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
01:14Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
01:15Parkinson's Disease: Overview
01:23Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
01:27Pharmacodynamics in Geriatric Patients: Effects of Age